Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Cabazitaxel Success Derail Other Prostate Cancer Trials?

Executive Summary

The release of positive Phase III results for Sanofi-Aventis' next-generation chemotherapy agent cabazitaxel in hormone-resistant prostate cancer could put a damper on recruitment for clinical trials of other late-stage drug trials in the same indication

You may also be interested in...



With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use

Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting

With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use

Sanofi-Aventis gained a fast approval for its chemotherapy Jevtana (cabazitaxel) - just 11 weeks after the final filing in a rolling submission for second-line treatment of advanced hormone-refractory prostate cancer. But the company is also positioned for a quick expansion to the first-line setting

Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain

Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel